Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGuIX Nanoparticles with Chemoradiation in Locally Advanced Cervical Cancer
NCT03308604Phase 1Unknown
- Sponsor
- Gustave Roussy
- Start
- May 2018
- Primary completion
- Jul 2022
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AGuIX in Cervical Cancer (CC), sponsored by Gustave Roussy. Primary endpoints: Maximum Tolerated Dose at Day 84 and Recommended Phase 2 Dose at Day 84. Status: unknown.
02
Drugs
AGuIX
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03308604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308604.